XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.1
CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
$ in Thousands
Series A
Preferred Stock
Series B
Preferred Stock
Series C
Preferred Stock
Common Stock
Additional paid-in capital
Subscription receivable
Accumulated deficit
Accumulated Other Comprehensive Income (Loss)
Total
Beginning balance at Dec. 31, 2020 $ 34,992 $ 144,839              
Beginning balance (in shares) at Dec. 31, 2020 35,000,000 26,143,790              
Increase (Decrease) in Temporary Equity [Roll Forward]                  
Issuance of Series C preferred stock, net     $ 159,628            
Issuance of Series C preferred stock, net (in shares)     24,721,999            
Ending balance at Mar. 31, 2021 $ 34,992 $ 144,839 $ 159,628            
Ending balance (in shares) at Mar. 31, 2021 35,000,000 26,143,790 24,721,999            
Beginning balance at Dec. 31, 2020       $ 1 $ 217,832 $ (31,900) $ (292,342) $ (3) $ (106,412)
Beginning Balance (in shares) at Dec. 31, 2020       7,481,861          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Receipt of subscription receivable           $ 31,900     31,900
Net assets contributed as result of merger         1,061       1,061
Issuance of common stock upon the exercise of stock options         47       47
Issuance of common stock upon the exercise of stock options (in shares)       40,790          
Vesting of restricted stock (in shares)       150,799          
Vesting of early exercise stock options         123       123
Vesting of early exercise stock options (in shares)       199,083          
Unrealized loss on investments               (27) (27)
Foreign currency translation               4 4
Stock based compensation expense         95       95
Net loss             (18,348)   (18,348)
Ending balance at Mar. 31, 2021       $ 1 219,158   (310,690) (26) (91,557)
Ending Balance (in shares) at Mar. 31, 2021       7,872,533          
Beginning balance at Dec. 31, 2021       $ 5 785,049   (388,166) (650) 396,238
Beginning Balance (in shares) at Dec. 31, 2021       55,005,523          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of stock to collaboration partner       $ 1 26,812       26,813
Issuance of stock to collaboration partner (in shares)       2,160,760          
Issuance of common stock upon the exercise of stock options         65       65
Issuance of common stock upon the exercise of stock options (in shares)       85,396          
Vesting of restricted stock (in shares)       161,159          
Vesting of early exercise stock options         673       673
Vesting of early exercise stock options (in shares)       173,192          
Unrealized loss on investments               (1,986) (1,986)
Foreign currency translation               (6) (6)
Stock based compensation expense         2,380       2,380
Net loss             (37,513)   (37,513)
Ending balance at Mar. 31, 2022       $ 6 $ 814,979   $ (425,679) $ (2,642) $ 386,664
Ending Balance (in shares) at Mar. 31, 2022       57,586,030